The company's expenditure during the same period increased by only 6.19% from Rs 447.85 crore to Rs 475.56 crore.
At the same time interest income also increased from Rs 16.62 crore to Rs 41.19 meanwhile other income increased marginally by 16% yoy to Rs 38.47 crore.
The company managed to increase its net profit from 322.63 crore to Rs 423.2 crore, representing growth of 31.17% yoy.
On a consolidated basis the company said that its figures were not comparable to the previous quarters due to the acquisition of Israel's Taro Pharmaceutical Industries, which became its subsidiary in September last year.
The company also said in its press statement that sale of branded prescription formulations in India was at Rs 638 crore for the first quarter. It grew 12% over the same quarter of last year, and it forms 39% of total sales. Excluding third party business, the growth was 18%.
Consolidated R&D expense for Q1 FY12 is 93 crores, of 6% of sales.